Akademik Veri Yönetim Sistemi
CANCERS, cilt.14, sa.4, 2022 (SCI-Expanded)
Simple Summary: Transforming growth factor beta (TGF-beta) signaling is a preeminent regulator of diverse cellular and physiological processes. Frequent dysregulation of TGF-beta signaling has been implicated in cancer. In hepatocellular carcinoma (HCC), the most prevalent form of primary liver cancer, the autocrine and paracrine effects of TGF-beta have paradoxical implications. While acting as a potent tumor suppressor pathway in the early stages of malignancy, TGF-beta diverts to a promoter of tumor progression in the late stages, reflecting its bright and dark natures, respectively. Within this context, targeting TGF-beta represents a promising therapeutic option for HCC treatment. We discuss here the molecular properties of TGF-beta signaling in HCC, attempting to provide an overview of its effects on tumor cells and the stroma. We also seek to evaluate the dysregulation mechanisms that mediate the functional switch of TGF-beta from a tumor suppressor to a pro-tumorigenic signal. Finally, we reconcile its biphasic nature with the therapeutic implications.Hepatocellular carcinoma (HCC) is associated with genetic and nongenetic aberrations that impact multiple genes and pathways, including the frequently dysregulated transforming growth factor beta (TGF-beta) signaling pathway. The regulatory cytokine TGF-beta and its signaling effectors govern a broad spectrum of spatiotemporally regulated molecular and cellular responses, yet paradoxically have dual and opposing roles in HCC progression. In the early stages of tumorigenesis, TGF-beta signaling enforces profound tumor-suppressive effects, primarily by inducing cell cycle arrest, cellular senescence, autophagy, and apoptosis. However, as the tumor advances in malignant progression, TGF-beta functionally switches to a pro-tumorigenic signal, eliciting aggressive tumor traits, such as epithelial-mesenchymal transition, tumor microenvironment remodeling, and immune evasion of cancer cells. On this account, the inhibition of TGF-beta signaling is recognized as a promising therapeutic strategy for advanced HCC. In this review, we evaluate the functions and mechanisms of TGF-beta signaling and relate its complex and pleiotropic biology to HCC pathophysiology, attempting to provide a detailed perspective on the molecular determinants underlying its functional diversion. We also address the therapeutic implications of the dichotomous nature of TGF-beta signaling and highlight the rationale for targeting this pathway for HCC treatment, alone or in combination with other agents.